Semaglutide protocol to analyze vascular structure and function in early Type 2 Diabetes patients
Background
Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and impaired insulin secretion, often leading to significant cardiovascular complications. Current treatments primarily focus on glycemic control, but residual cardiovascular risk remains high, particularly affecting both macro- and microcirculation. GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular benefits in established T2D, but their specific effects on vascular structure and function, especially in early disease stages, require further elucidation. This study aims to fill this knowledge gap by investigating semaglutide's direct impact on vascular parameters.
Study Design
This is a phase IV, randomized (1:1), prospective, double-blind, placebo-controlled, parallel-group, single-center study. At least 90 patients with early Type 2 Diabetes will be randomized to receive either semaglutide or placebo. The intervention involves weekly subcutaneous (SC) injections, starting with 0.25 mg semaglutide and up-titrating to 0.5 mg and then 1.0 mg at visits 4 and 5, respectively. Baseline vascular function parameters will be obtained at visit 2. The primary objective is to analyze the effect of semaglutide on central (aortic) pulse pressure.
Results
This abstract describes the protocol for a clinical trial, and as such, no results or specific numerical findings are available yet. The study's main goal is to demonstrate the effect of semaglutide on various vascular parameters of both macro- and microcirculation. The trial is designed to obtain 80 fully evaluable subjects from the 90 patients randomized.
The primary objective is to analyze the effect of semaglutide, compared to placebo, on central (aortic) pulse pressure. Secondary objectives will likely include other measures of vascular structure and function, which will be assessed throughout the study duration, providing a comprehensive understanding of semaglutide's vascular effects.
Key Findings
- Primary objective: Analyze semaglutide's effect on central (aortic) pulse pressure in early Type 2 Diabetes.
- Secondary objective: Investigate semaglutide's impact on other macro- and microcirculation vascular parameters.
- Study design: Phase IV, randomized, double-blind, placebo-controlled, parallel-group trial with 90 patients.
- Dosing protocol: Weekly SC injections of semaglutide, up-titrating from 0.25 mg to 0.5 mg and 1.0 mg.
Why It Matters
This study is crucial for understanding the direct vascular benefits of semaglutide beyond glycemic control, particularly in the early stages of Type 2 Diabetes. If positive, findings could support earlier intervention with GLP-1R agonists to mitigate cardiovascular disease progression. For peptide users and clinicians, this could refine treatment strategies, potentially leading to protocols that prioritize vascular health earlier in the disease course. The up-titration schedule (0.25 mg, 0.5 mg, 1.0 mg weekly SC) provides a clinically relevant dosing regimen. This research could inform future guidelines on the comprehensive management of T2D, emphasizing proactive cardiovascular protection.
semaglutide
type-2-diabetes
cardiovascular-health
vascular-function
clinical-trial
glp-1-agonist